Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier.

Doxorubicin (DXR) commonly used in cancer therapy produces undesirable side effects such as cardiotoxicity. To minimize these, attempts have been made to couple the drug with dextran (DEX) and then to encapsulate this drug conjugate in hydrogel nanoparticles. By encapsulation of the drug conjugate in biodegradable, biocompatible long circulating hydrogel nanoparticles, we further improved the therapeutic efficacy of the conjugate. The size of these nanoparticles as determined by quasi-elastic light scattering, was found to be 100+/-10 nm diameter, which favors the enhanced permeability and retention effect (EPR) as observed in most solid tumors. The antitumor effect of these DEX-DXR nanoparticles, was evaluated in J774A.1 macrophage tumor cells implanted in Balb/c mice. The in vivo efficacy of these nanoparticles as antitumor drug carriers, was determined by tumor regression and increased survival time as compared to drug conjugate and free drug. These results suggest that encapsulation of the conjugate in nanoparticles not only reduces the side effects, but also improves its therapeutic efficacy in the treatment of solid tumors.

[1]  A. Jayakrishnan,et al.  Glutaraldehyde cross-linked chitosan microspheres as a long acting biodegradable drug delivery vehicle: studies on the in vitro release of mitoxantrone and in vivo degradation of microspheres in rat muscle. , 1995, Biomaterials.

[2]  S. Davis,et al.  Biomedical applications of nanotechnology--implications for drug targeting and gene therapy. , 1997, Trends in biotechnology.

[3]  J. Kopeček,et al.  Controlled Release of Drug Model from N‐(2‐Hydroxypropyl)‐methacrylamide Copolymers , 1985, Annals of the New York Academy of Sciences.

[4]  R. Ozols,et al.  The anthracycline antineoplastic drugs. , 1981, The New England journal of medicine.

[5]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[6]  Drug targeting in cancer therapy: the magic bullet, what next? , 1996, Journal of drug targeting.

[7]  A. Meshorer,et al.  Reduced toxicity of daunorubicin by conjugation to dextran. , 1982, Cancer treatment reports.

[8]  M. Wilchek,et al.  Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. , 1978, Journal of the National Cancer Institute.

[9]  A. Rahman,et al.  Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. , 1986, British Journal of Cancer.

[10]  A. Maitra,et al.  Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. , 2000, International journal of pharmaceutics.

[11]  P Buri,et al.  Chitosan: a unique polysaccharide for drug delivery. , 1998, Drug development and industrial pharmacy.

[12]  H. Maeda,et al.  Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. , 1992, Bioconjugate chemistry.